Idera Completes Recruitment In Late-Stage Melanoma Study
Zacks Investment Research | Mar 05, 2020 11:14PM ET
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) announced that it has completed patient enrollment in the phase III ILLUMINATE-301 study, evaluating tilsotolimod in combination with Bristol-Myers’ (NYSE:BMY) Yervoy (ipilimumab) for treating patients with anti-PD-1 refractory advanced melanoma.
Top-line overall response rate (ORR) and other preliminary data from this late-stage registrational ILLUMINATE-301 study are expected in the first quarter of 2021.
Per the company, tilsotolimod is an investigational an agonist of Toll-like receptor 9, which is being developed via intratumoral injection for addressing the given indication.
The randomized, ILLUMINATE-301 study is evaluating the effectiveness of intratumoral tilsotolimod in combination with Yervoy in patients with anti-PD-1 refractory advanced melanoma compared to Yervoy alone.
The primary endpoint of the study is ORR and the overall survival (OS) while the secondary endpoints include durable response rate, time to response, progression-free survival, safety and patient-reported outcomes.
Shares of Idera have plunged 41.9% in the past year compared with the Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.